You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
騰盛博藥一度暴漲36% 安巴韋單抗/羅米司韋單抗注射液被寫入最新診療方案
格隆匯 03-16 09:50
格隆匯3月16日丨騰盛博藥(2137.HK)盤初拉昇一度暴漲36%至11.4港元。消息面上,國家衞健委昨日發佈《新型冠狀病毒肺炎診療方案(試行第九版)》,將國家藥監局批准的兩種特異性抗新冠病毒藥物PF-07321332/利托那韋片(Paxlovid)和國產單克隆抗體(安巴韋單抗/羅米司韋單抗注射液)寫入診療方案。安巴韋單抗/羅米司韋單抗聯合療法正是騰盛博藥的產品,2021年12月8日獲國家藥品監督管理局(NMPA)上市批准,用於治療輕型和普通型且伴有進展為重型(包括住院或死亡)高風險因素的成人和青少年(12-17歲,體重≥40kg)新型冠狀病毒感染(COVID-19)患者。其中青少年(12-17歲,體重≥40kg)適應症人羣為附條件批准。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account